secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002940
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio raises $26M in PIPE led by Frazier Life Sciences to fund cardiometabolic programs
--------------------------------------------------------------------------------

- Gross proceeds of ~$26M from sale of 11.06M shares/pre-funded warrants at $2.35/share.
- Expected close on Jan 13, 2026; led by Frazier Life Sciences with other existing investors.
- Proceeds to advance IBIO-610, IBIO-600, and myostatin/activin A bispecific programs.
- Company expects cash runway extended into calendar 2028.
- Leerink Partners lead placement agent; LifeSci Capital and Oppenheimer co-agents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000110465926002940/0001104659-26-002940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000110465926002940/tm262944d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer